Idalopirdine (INN) (code names Lu AE58054,) is a potent and selective 5-HT6 receptor antagonist under development by Lundbeck as an augmentation therapy for the treatment of cognitive deficits associated with Alzheimer's disease and schizophrenia.[1][2] As of October 2013 it is in phase III clinical trials.[2]
Clinical data | |
---|---|
Other names | Lu-AE-58054 |
ATC code |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
ChemSpider |
|
UNII |
|
KEGG |
|
ChEMBL |
|
ECHA InfoCard | 100.245.270 |
Chemical and physical data | |
Formula | C20H19F5N2O |
Molar mass | 398.377 g·mol−1 |
3D model (JSmol) |
|
| |
| |
(what is this?) (verify) |
A phase III trial of two different daily doses of Lu AE58054 on top of 10 mg of donepezil for mild-to-moderate Alzheimer's failed to meet its primary endpoint with either dose.[3] Two further phase III trials failed too, the company confirmed in early 2017.[3]